Zacks Investment Research upgraded shares of Synthetic Biologics (NYSEAMERICAN:SYN) from a hold rating to a buy rating in a research report released on Tuesday morning. The firm currently has $0.25 target price on the stock.
According to Zacks, “Synthetic Biologics, Inc. is a biotechnology company focused on the development of synthetic DNA-based therapeutics and innovative disease-modifying medicines for serious illnesses. The Company is engaged in developing product candidates to treat pulmonary arterial hypertension, relapses in multiple sclerosis, cognitive dysfunction in multiple sclerosis, fibromyalgia and amyotrophic lateral sclerosis. Synthetic Biologics, Inc., formerly known as Adeona Pharmaceuticals, Inc., is headquartered in Ann Arbor, Michigan. “
Other equities research analysts have also recently issued reports about the company. HC Wainwright restated a buy rating and set a $35.00 target price on shares of Synthetic Biologics in a report on Thursday, August 9th. Griffin Securities cut Synthetic Biologics from a buy rating to a hold rating in a report on Wednesday, May 9th. Two analysts have rated the stock with a sell rating, one has issued a hold rating and two have assigned a buy rating to the stock. The company has an average rating of Hold and a consensus target price of $17.63.
Synthetic Biologics (NYSEAMERICAN:SYN) last announced its quarterly earnings data on Wednesday, August 8th. The company reported ($1.05) EPS for the quarter, beating the consensus estimate of ($1.40) by $0.35.
An institutional investor recently raised its position in Synthetic Biologics stock. Blair William & Co. IL grew its holdings in Synthetic Biologics Inc (NYSEAMERICAN:SYN) by 14.8% in the 1st quarter, according to the company in its most recent filing with the SEC. The firm owned 1,980,857 shares of the company’s stock after buying an additional 255,096 shares during the quarter. Blair William & Co. IL owned approximately 1.54% of Synthetic Biologics worth $631,000 at the end of the most recent quarter.
Synthetic Biologics Company Profile
Synthetic Biologics, Inc, a late-stage clinical company, develops therapeutics designed to preserve the microbiome to protect and restore the health of patients. Its lead product candidates are in Phase III development, such as SYN-004 that is designed to protect the gut microbiome from the effects of commonly used intravenous (IV) beta-lactam antibiotics for the prevention of C.
Recommended Story: How are Outstanding Shares Different from Authorized Shares?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Synthetic Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synthetic Biologics and related companies with MarketBeat.com's FREE daily email newsletter.